CID-5056270
CAS No. 681173-76-2
CID-5056270( —— )
Catalog No. M33971 CAS No. 681173-76-2
CID-5056270 has anticancer activity and can inhibit lung cancer, anal cancer, bladder cancer, cervical cancer, vulvar cancer, penile cancer, Burkitt's lymphoma, breast cancer and bone cancer.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 446 | In Stock |
|
| 5MG | 440 | In Stock |
|
| 10MG | 613 | In Stock |
|
| 25MG | 905 | In Stock |
|
| 50MG | 1209 | In Stock |
|
| 100MG | 1609 | In Stock |
|
| 200MG | 2167 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameCID-5056270
-
NoteResearch use only, not for human use.
-
Brief DescriptionCID-5056270 has anticancer activity and can inhibit lung cancer, anal cancer, bladder cancer, cervical cancer, vulvar cancer, penile cancer, Burkitt's lymphoma, breast cancer and bone cancer.
-
DescriptionCID-5056270 has anticancer activity and can inhibit lung cancer, anal cancer, bladder cancer, cervical cancer, vulvar cancer, penile cancer, Burkitt's lymphoma, breast cancer and bone cancer. It can be used to study hypertension, Alzheimer's disease and arteriosclerosis.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayCell Cycle/DNA Damage
-
TargetROCK
-
RecptorROCK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number681173-76-2
-
Formula Weight339.37
-
Molecular FormulaC17H13N3O3S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESN(C(=O)C1OC=2C(OC1)=CC=CC2)C3=NC(=CS3)C=4C=CN=CC4
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
Y27632
Y-27632 is a selective ROCK1 (p160ROCK) inhibitor with Ki of 140 nM in a cell-free assay.
-
CRT0066854 hydrochlo...
CRT0066854 hydrochloride is an effective selective atypical PKCs inhibitor.
-
Cucurbitacin A
Cucurbitacin I, cytotoxic triterpenoid sterols isolated from plants, elicits the formation of actin/phospho-myosin II co-aggregates by stimulation of the RhoA/ROCK pathway and inhibition of LIM-Kinase.
Cart
sales@molnova.com